SAB Biotherapeutics (SABS) News Today $2.19 +0.02 (+0.92%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$2.15 -0.04 (-1.83%) As of 01/31/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period SAB Biotherapeutics' (SABS) "Buy" Rating Reiterated at HC WainwrightFebruary 1 at 3:43 AM | americanbankingnews.comSAB Biotherapeutics' (SABS) "Buy" Rating Reiterated at Chardan CapitalFebruary 1 at 3:43 AM | americanbankingnews.comSAB BIO to Participate in Upcoming Investor ConferencesJanuary 31 at 7:00 AM | globenewswire.comStrong Buy Recommendation for SAB-142: Promising Phase 1 Results and Future Market Potential in T1D TreatmentJanuary 29 at 9:12 PM | markets.businessinsider.comSAB Biotherapeutics, Inc.: SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142January 29 at 5:43 AM | finanznachrichten.deSAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142January 28, 2025 | globenewswire.comSAB Biotherapeutics (SABS) Gets a Buy from Craig-HallumJanuary 25, 2025 | markets.businessinsider.comSAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D TherapyJanuary 23, 2025 | globenewswire.comSAB Biotherapeutics Leads The Pack Of 3 US Penny Stocks To ConsiderDecember 23, 2024 | finance.yahoo.comSAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023)November 9, 2024 | finance.yahoo.comPromising Outlook for SAB Biotherapeutics’ SAB-142 in Type 1 Diabetes Treatment Drives Buy RatingNovember 7, 2024 | markets.businessinsider.comSAB BIO Announces Third Quarter 2024 Financial Results and Provides Company UpdateNovember 6, 2024 | globenewswire.comCraig-Hallum Remains a Buy on SAB Biotherapeutics (SABS)October 15, 2024 | markets.businessinsider.comCraig-Hallum Initiates Coverage of SAB Biotherapeutics (SABS) with Buy RecommendationOctober 10, 2024 | msn.comSAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash WiselySeptember 23, 2024 | finance.yahoo.comSAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare ConferenceSeptember 13, 2024 | globenewswire.comSAB Biotherapeutics (SABS) Gets a Buy from OppenheimerSeptember 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: SAB Biotherapeutics (SABS) and Vor Biopharma (VOR)September 11, 2024 | markets.businessinsider.comSAB BIO to Present at the European Association for the Study of Diabetes 60th Annual MeetingSeptember 4, 2024 | globenewswire.comBuy Rating on SAB Biotherapeutics: Promising Developments in Type 1 Diabetes TreatmentAugust 29, 2024 | markets.businessinsider.comSAB Biotherapeutics, Inc.: SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company UpdatesAugust 10, 2024 | finanznachrichten.deAnalysts Offer Insights on Healthcare Companies: Sandoz Group Ltd (OtherSDZXF) and SAB Biotherapeutics (SABS)August 10, 2024 | markets.businessinsider.comSABS Stock Earnings: SAB Biotherapeutics Beats EPS for Q2 2024August 9, 2024 | investorplace.comSAB BIO Announces Second Quarter 2024 Financial Results and Provides Company UpdatesAugust 8, 2024 | globenewswire.comSAB Biotherapeutics, Inc.: SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 DiabetesAugust 7, 2024 | finanznachrichten.deSAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 DiabetesAugust 5, 2024 | globenewswire.comEx-Wells Fargo investment banker named CFO of pharma companyAugust 1, 2024 | bizjournals.comSAB BIO Appoints Lucy To as Chief Financial OfficerJuly 31, 2024 | globenewswire.comSAb Biotherapeutics Rebrands as SAB BIOJune 20, 2024 | globenewswire.comSAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific SessionsJune 18, 2024 | globenewswire.comSAB Biotherapeutics Announces Departure of Chief Financial OfficerMay 30, 2024 | globenewswire.comPharma company moves headquarters from Midwest to Miami BeachMay 25, 2024 | bizjournals.comSAB Biotherapeutics, Inc.: FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB BiotherapeuticsMay 21, 2024 | finanznachrichten.deSAB Biotherapeutics: Strong Buy Rating on Robust Financials and Promising Diabetes Drug DevelopmentMay 21, 2024 | markets.businessinsider.comSAB Biotherapeutics, Inc.: SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company UpdatesMay 21, 2024 | finanznachrichten.deSAB Biotherapeutics Gets FDA Clearance To Advance Phase 1 Trial Of SAB-142 In Type-1 DiabetesMay 21, 2024 | markets.businessinsider.comFDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB BiotherapeuticsMay 21, 2024 | globenewswire.comSAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company UpdatesMay 20, 2024 | globenewswire.comSAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of DirectorsMay 6, 2024 | globenewswire.comSAB Biotherapeutics (SABS) Price Target Decreased by 10.00% to 18.36April 17, 2024 | msn.comSAB Leaps on Completing Latest CohortApril 16, 2024 | msn.comSAB Biotherapeutics Provides SAB-142 Trial UpdateApril 16, 2024 | globenewswire.comSAB Biotherapeutics to Present at INNODIA Annual MeetingApril 8, 2024 | globenewswire.comSAB Biotherapeutics: Strong Financial Position and Promising SAB-142 Pipeline Merit Buy RatingApril 4, 2024 | markets.businessinsider.comSAB Biotherapeutics to Present at the Needham Virtual Healthcare ConferenceApril 4, 2024 | globenewswire.comSAB Biotherapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsApril 1, 2024 | finance.yahoo.comSAB Biotherapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsApril 1, 2024 | finance.yahoo.comSAB Biotherapeutics Reports Full Year 2023 Operating and Financial ResultsMarch 29, 2024 | globenewswire.comSAB Collaborates With Naval Medical Research To Develop Potential Influenza Treatment; Stock DropsMarch 25, 2024 | markets.businessinsider.comSAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza TreatmentMarch 25, 2024 | globenewswire.com Get SAB Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter. Email Address SABS Media Mentions By Week SABS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SABS News Sentiment▼0.520.69▲Average Medical News Sentiment SABS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SABS Articles This Week▼131▲SABS Articles Average Week Get SAB Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ACHV News Today AGEN News Today RGLS News Today FBIO News Today CRIS News Today BOLT News Today MTEM News Today AMGN News Today GILD News Today VRTX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SABS) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
